Guardant Health (NASDAQ:GH – Get Free Report) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it compare to its rivals? We will compare Guardant Health to similar companies based on the strength of its valuation, institutional ownership, profitability, earnings, risk, analyst recommendations and dividends.
Profitability
This table compares Guardant Health and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Guardant Health | -37.93% | N/A | -25.03% |
| Guardant Health Competitors | 1.61% | -135.40% | -1.32% |
Insider and Institutional Ownership
92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 5.6% of Guardant Health shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Providers & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Guardant Health | 1 | 0 | 24 | 1 | 2.96 |
| Guardant Health Competitors | 1890 | 7762 | 13426 | 840 | 2.55 |
Guardant Health presently has a consensus target price of $191.48, indicating a potential upside of 31.30%. As a group, “Healthcare Providers & Services” companies have a potential upside of 21.77%. Given Guardant Health’s stronger consensus rating and higher possible upside, analysts plainly believe Guardant Health is more favorable than its rivals.
Earnings & Valuation
This table compares Guardant Health and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Guardant Health | $982.02 million | -$416.28 million | -39.63 |
| Guardant Health Competitors | $21.13 billion | $301.67 million | -3.54 |
Guardant Health’s rivals have higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Guardant Health has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Guardant Health’s rivals have a beta of 0.98, suggesting that their average share price is 2% less volatile than the S&P 500.
Summary
Guardant Health beats its rivals on 7 of the 13 factors compared.
Guardant Health Company Profile
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
